AUG 14, 2018 11:20 PM PDT

New Drug for Refractory Cutaneous T-cell Lymphoma

There are two types of cutaneous T-cell lymphoma, or CTCL, which fall under the non-Hodgkin’s Lymphoma umbrella; Mycosis Fungoides (MF) presents with skin patches or tumorous plaques and Sezary Syndrome (SS) presents with a thin itchy rash and must also involve lymphoma cells in the bloodstream.  CTCL is one of the most common types of T-cell lymphoma.  Current treatment options include both topical and systemic therapies depending on the extent of disease at the time of diagnosis.  While many patients can complete traditional treatment and live healthy lives, there are a subset of patients with relapsed or refractory disease which becomes harder to treat.  This group of patients have not had many options until now.  The FDA has just recently approved a new drug called mogamulizumab-kpkc (Poteligeo, Kyowa Hakko Kirin Pharma), which is specific for MF and SS which are harder to treat types of non-Hodgkin’s lymphoma. 

Mogamulizumab-kpkc is a directed monoclonal antibody that binds to a specific chemokine receptor, CCR4.  This receptor expression is found on cells involved in our innate and adaptive immune systems and has been documented as a present marker in CTCL.  A large phase III clinical trial (NCT01728805) compared this drug mogamulizumab-kpkc, named KW-0761, with the current vorinostat (Zolinza, Merck) therapy for CTCL.  The study involved 372 participants across the United States, Australia, multiple countries in Europe, and Japan.  Progression free survival was significant for those participants receiving KW-0761.  While there were some adverse reactions reported, the drug is a breakthrough and Cfills a needed gap for patients with these types of T-cell lymphomas. 

Mogamulizumab acts by reducing the number of CCR4-expressing cells through the well described process of antibody dependent, cell-mediated cytotoxicity.  This is an immune system response using Fc receptor effector cells which recognize and destroy targeted cells identified by the specific antibodies covering their pathogenic antigens.  In this case, the pathogenic antigen is CCR4.  The antibody dependent, cell-mediated cytotoxicity pathway utilizes cytotoxic granule release and is already used in the body for protection against infectious diseases.  The model for monoclonal antibody use in cancer therapy has been proven effective over the past few years of research and clinical application.

Sources: FDA, Lymphoma Research Foundation, Blood, Academic Press,

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
NOV 21, 2019
Cancer
NOV 21, 2019
What zebra fish tell us about cancer tumors
New research published in PNAS from researchers at Duke University highlights a surprising finding: zebrafish have the ability to shed the lining of their ...
NOV 21, 2019
Cancer
NOV 21, 2019
Could electromagnetic fields treat metastatic triple-negative breast cancer?
New research published in Communications Biology suggests that electromagnetic fields are capable of stopping the metastasis of some breast cancer cells. I...
NOV 21, 2019
Cancer
NOV 21, 2019
Handheld device detects skin cancer
I can’t be the only one who has ever looked at a suspicious freckle and wondered, “Could this be skin cancer?” Of course, when 9,500 Amer...
NOV 21, 2019
Cancer
NOV 21, 2019
Using temperature to awaken immune response to fight brain cancer
Glioblastoma is the most common form of adult brain cancer and also one of the most aggressive human cancers. Immunotherapy has yet to be shown proven effe...
NOV 21, 2019
Cancer
NOV 21, 2019
An alternative for immunotherapy-resistant cancer patients
A twist to traditional immunotherapies could help cancer patients’ immune systems better detect cancer cells, making this new system capable of targe...
NOV 21, 2019
Clinical & Molecular DX
NOV 21, 2019
New diagnostic technology seeks out cancer DNA in blood
For many cancers, early detection has a tremendous impact on patient outcomes. Yet, sadly, many of the most common malignancies, like those of the stomach,...
Loading Comments...